|
US5833975A
(en)
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
|
DE69233158T2
(de)
|
1991-03-07 |
2004-05-13 |
Connaught Technology Corp., Greenville |
Gentechnologisch hergestellter stamm für impfstoffe
|
|
ATE298370T1
(de)
|
1994-04-29 |
2005-07-15 |
Baxter Healthcare Sa |
Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
|
|
US6093700A
(en)
|
1995-05-11 |
2000-07-25 |
Thomas Jefferson University |
Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
|
|
DE69519521T2
(de)
|
1994-10-03 |
2001-06-28 |
The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US6004777A
(en)
|
1997-03-12 |
1999-12-21 |
Virogenetics Corporation |
Vectors having enhanced expression, and methods of making and uses thereof
|
|
US20030044384A1
(en)
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
WO2000073487A1
(en)
|
1999-05-27 |
2000-12-07 |
Arizona Board Of Regents |
Novel viral vectors having enhanced effectiveness with dramatically reduced virulence
|
|
WO2000073479A1
(en)
|
1999-05-28 |
2000-12-07 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
|
|
BR0015491A
(pt)
|
1999-11-12 |
2002-10-15 |
Oncolytics Biotech Inc |
Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
MXPA03004298A
(es)
|
2000-11-20 |
2004-02-12 |
Oncolytics Biotech Inc |
Metodo para transmitir optimamente virus a masa de tumor solido.
|
|
UA76731C2
(uk)
|
2000-11-23 |
2006-09-15 |
Баваріан Нордік А/С |
Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
|
|
US6750043B2
(en)
|
2001-04-19 |
2004-06-15 |
Arizona Board Of Regents |
Viral vectors having reduced virulence
|
|
US6372455B1
(en)
|
2001-04-19 |
2002-04-16 |
Arizona Board Of Regents |
Recombinant vaccinia viral vectors
|
|
US20040091995A1
(en)
|
2001-06-15 |
2004-05-13 |
Jeffrey Schlom |
Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
|
|
US20030113919A1
(en)
|
2001-08-17 |
2003-06-19 |
Aventis Pasteur, Ltd. |
Immunogenic targets for melanoma
|
|
DE10144664B4
(de)
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
|
US7001718B2
(en)
|
2001-12-20 |
2006-02-21 |
Massachusetts Institute Of Technology |
Method of inhibiting pathogenicity of infectious agents
|
|
CN100540051C
(zh)
|
2002-04-19 |
2009-09-16 |
巴法里安诺迪克有限公司 |
用于接种新生儿的改良的安卡拉痘苗病毒
|
|
US20070178065A1
(en)
|
2002-05-03 |
2007-08-02 |
Lattime Edmund C |
Neutralizing factors as vaccine adjuvants
|
|
DE10221411B4
(de)
|
2002-05-14 |
2004-07-08 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Rekombinantes Fowlpox-Virus
|
|
ATE315660T1
(de)
|
2002-05-16 |
2006-02-15 |
Bavarian Nordic As |
Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
|
|
WO2004042001A2
(en)
|
2002-05-17 |
2004-05-21 |
Emory University |
Virus-like particles, methods of preparation, and immonogenic compositions
|
|
JP2004031674A
(ja)
|
2002-06-26 |
2004-01-29 |
Disco Abrasive Syst Ltd |
コンタミネーション除去装置
|
|
AU2003249059A1
(en)
|
2002-07-24 |
2004-02-09 |
Arizona Board Of Regents |
Use of vaccinia virus deleted for the e3l gene as a vaccine vector
|
|
AU2003267361A1
(en)
|
2002-09-12 |
2004-04-30 |
Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh |
Orthopoxvirus antigens and use thereof
|
|
CA2511625A1
(en)
|
2002-12-23 |
2004-07-15 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
|
WO2004087047A2
(en)
|
2003-02-07 |
2004-10-14 |
Arizona Board Of Regents |
Mutants of replication competent vaccinia virus
|
|
ATE420160T1
(de)
|
2003-06-18 |
2009-01-15 |
Genelux Corp |
Modifizierte rekombinante vacciniaviren, verwendungen davon
|
|
WO2005007824A2
(en)
|
2003-07-08 |
2005-01-27 |
Arizona Board Of Regents |
Mutants of vaccinia virus as oncolytic agents
|
|
CA2435967A1
(en)
|
2003-07-25 |
2005-01-25 |
Oncolytics Biotech, Inc. |
Reovirus for the treatment of lymphoid malignancies
|
|
CA2436196A1
(en)
|
2003-07-25 |
2005-01-25 |
Oncolytics Biotech Inc. |
Oncolytic virus for purging cellular compositions of cells of lymphoid malignancies
|
|
WO2005028634A2
(en)
|
2003-09-18 |
2005-03-31 |
Emory University |
Improved mva vaccines
|
|
EP1518932A1
(en)
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
EP1786474B1
(en)
*
|
2004-08-12 |
2011-06-01 |
Cedars-Sinai Medical Center |
Combined gene therapy for the treatment of macroscopic gliomas
|
|
EP1683870A1
(en)
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
WO2006120474A2
(en)
|
2005-05-13 |
2006-11-16 |
Oxxon Therapeutics Ltd |
Compositions for inducing an immune response against tumor antigens
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
US20070077231A1
(en)
|
2005-09-30 |
2007-04-05 |
Contag Christopher H |
Immune effector cells pre-infected with oncolytic virus
|
|
EP1989224B1
(en)
|
2006-02-24 |
2010-10-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Immunogenic peptides and methods of use
|
|
KR100788930B1
(ko)
|
2006-04-18 |
2007-12-27 |
포항공과대학교 산학협력단 |
항암 조성물
|
|
DK2596801T3
(en)
|
2006-10-06 |
2018-08-13 |
Bavarian Nordic As |
RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
|
|
EP2097517B1
(en)
|
2006-10-16 |
2014-06-04 |
Genelux Corporation |
Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
|
|
WO2008108890A2
(en)
|
2006-10-18 |
2008-09-12 |
University Of Rochester |
Conditionally replicating viruses for cancer therapy
|
|
KR20080084528A
(ko)
*
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
|
CA2690627C
(en)
|
2007-06-15 |
2014-12-02 |
Genelux Corporation |
Microorganisms for imaging and/or treatment of tumors
|
|
JP2010533718A
(ja)
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
|
AU2008312444B2
(en)
|
2007-10-18 |
2014-02-06 |
Bavarian Nordic A/S |
Use of MVA to treat prostate cancer
|
|
JP2011500608A
(ja)
|
2007-10-22 |
2011-01-06 |
オンコリティクス バイオテク，インコーポレーテッド |
増殖性障害の治療レジメン
|
|
RU2503717C2
(ru)
|
2007-11-19 |
2014-01-10 |
Трансжене Са |
Поксвирусные онколитические векторы
|
|
HRP20150360T1
(hr)
|
2007-11-19 |
2015-05-08 |
Transgene Sa |
Poksvirusni onkolitiäśki vektori
|
|
US20120052003A9
(en)
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009152179A1
(en)
|
2008-06-09 |
2009-12-17 |
Arizona Board Of Regents |
Compositions, methods, and kits for eliciting an immune response
|
|
EP2349296B1
(en)
|
2008-08-21 |
2017-04-05 |
Ottawa Hospital Research Institute |
Engineered synergistic oncolytic viral symbiosis
|
|
EP2424999A1
(en)
|
2009-04-30 |
2012-03-07 |
Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) |
Modified immunization vectors
|
|
CA2709292A1
(en)
|
2009-07-10 |
2011-01-10 |
The Governors Of The University Of Alberta |
Oncolytic viruses and methods for treating neoplastic disorders
|
|
ES2848650T3
(es)
|
2009-09-14 |
2021-08-11 |
Sillajen Biotherapeutics Inc |
Terapia combinada contra el cáncer con virus vaccinia oncolítico
|
|
GB201006405D0
(en)
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
WO2011156470A1
(en)
|
2010-06-08 |
2011-12-15 |
Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University |
A method for inserting genetic material into genomic dna
|
|
US20130230884A1
(en)
|
2010-07-16 |
2013-09-05 |
John Chaput |
Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
|
|
JP2013538577A
(ja)
|
2010-09-23 |
2013-10-17 |
バクスター・インターナショナル・インコーポレイテッド |
組み換えウイルスベクターおよび黄熱病ウイルスに対する免疫反応を惹起するための方法
|
|
AU2012204467B2
(en)
|
2011-01-04 |
2016-08-18 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
|
ES2733211T3
(es)
|
2011-04-15 |
2019-11-28 |
Genelux Corp |
Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
|
|
FI20115914L
(fi)
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
WO2013063348A1
(en)
|
2011-10-28 |
2013-05-02 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Genetic element that enhances protein translation
|
|
US20140087362A1
(en)
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
WO2014031693A1
(en)
|
2012-08-20 |
2014-02-27 |
Genelux Corporation |
Compositions containing protein polymers and vaccinia virus, and methods of use thereof
|
|
KR20210008155A
(ko)
|
2012-08-30 |
2021-01-20 |
암젠 인크 |
단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
|
|
WO2014037124A1
(en)
|
2012-09-04 |
2014-03-13 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
|
US20150250837A1
(en)
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
TWI690322B
(zh)
|
2012-10-02 |
2020-04-11 |
法商傳斯堅公司 |
含病毒的調配物及其使用
|
|
EP2908851A1
(en)
|
2012-10-19 |
2015-08-26 |
Bavarian Nordic Inc. |
Methods and compositions for the treatment of cancer
|
|
US20180200320A1
(en)
|
2012-11-21 |
2018-07-19 |
Aviratek Biomedical Solutions, Llc |
Method and compositions for the use of botanical extracts in the treatment of viral infections, cancer, pain, itch, and inflammation
|
|
US20140193859A1
(en)
|
2013-01-08 |
2014-07-10 |
Bertram Jacobs |
Temperature-dependent insertion of genetic material into genomic DNA
|
|
US20140271549A1
(en)
|
2013-03-15 |
2014-09-18 |
Aladar A. Szalay |
Use of Antibiotics to Enhance Treatment With Therapeutic Viruses
|
|
WO2014193973A2
(en)
|
2013-05-28 |
2014-12-04 |
Dcb-Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
GB201310917D0
(en)
|
2013-06-19 |
2013-07-31 |
Cancer Res Inst Royal |
Vaccinia virus for gene-directed enzyme prodrug therapy
|
|
RS65104B1
(sr)
|
2013-08-22 |
2024-02-29 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Onkolitičke imunoterapije
|
|
WO2015066715A1
(en)
|
2013-11-04 |
2015-05-07 |
Viracell Advanced Products, Llc |
Virus-like particles and methods related thereto
|
|
AU2014347004B2
(en)
|
2013-11-05 |
2019-08-08 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
|
|
CN106061488B
(zh)
*
|
2013-12-02 |
2021-04-09 |
菲奥医药公司 |
癌症的免疫治疗
|
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
|
US20170106065A1
(en)
|
2013-12-31 |
2017-04-20 |
Bavarian Nordic A/S |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
|
|
WO2015138471A1
(en)
|
2014-03-10 |
2015-09-17 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Heat inactivated poxvirus improves vaccination results
|
|
WO2015138741A1
(en)
|
2014-03-12 |
2015-09-17 |
Cars-N-Kids Llc |
Systems and methods for determining if a child safety seat is in a moving vehicle
|
|
GB201405834D0
(en)
|
2014-04-01 |
2014-05-14 |
Univ London Queen Mary |
Oncolytic virus
|
|
KR102499737B1
(ko)
|
2014-05-13 |
2023-02-13 |
버베리안 노딕 에이/에스 |
종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
|
|
RU2696312C2
(ru)
|
2014-07-16 |
2019-08-01 |
Трансген Са |
Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
JP2017530114A
(ja)
|
2014-09-26 |
2017-10-12 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
|
|
KR101645642B1
(ko)
|
2014-10-16 |
2016-08-11 |
대한민국 |
Kvac１０３ 유래의 재조합 백시니아 바이러스
|
|
EP4523756A3
(en)
|
2015-02-13 |
2025-05-28 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
CN115300622A
(zh)
|
2015-02-25 |
2022-11-08 |
纪念斯隆-凯特琳癌症中心 |
使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
|
|
CN107847534B
(zh)
|
2015-04-17 |
2022-10-04 |
纪念斯隆凯特琳癌症中心 |
Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
|
|
US10967015B2
(en)
|
2015-06-15 |
2021-04-06 |
New York University |
Method of treatment using oncolytic viruses
|
|
JP6827467B2
(ja)
|
2015-06-19 |
2021-02-10 |
シルラジェン，インコーポレイテッド |
ウイルス塞栓術のための組成物および方法
|
|
CN105039269A
(zh)
|
2015-07-24 |
2015-11-11 |
北京鼎成肽源生物技术有限公司 |
一种用于治疗非小细胞肺癌的新型病毒疫苗及其制备方法
|
|
EP4137150A1
(en)
|
2015-08-03 |
2023-02-22 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
|
|
WO2017043815A1
(en)
|
2015-09-08 |
2017-03-16 |
Sillajen, Inc. |
Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof
|
|
EP3347473A4
(en)
|
2015-09-09 |
2019-04-10 |
Tvax Biomedical I, LLC |
METHOD FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ATTACHMENT THERAPY
|
|
US11266726B2
(en)
|
2015-10-30 |
2022-03-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the treatment of HER2-expressing solid tumors
|
|
BR112018012180A2
(pt)
|
2015-12-17 |
2018-12-04 |
Psioxus Therapeutics Ltd |
vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
|
|
ES2921605T3
(es)
|
2016-01-29 |
2022-08-30 |
Bavarian Nordic As |
Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
|
|
IL261321B2
(en)
|
2016-02-25 |
2023-12-01 |
Memorial Sloan Kettering Cancer Center |
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
|
|
KR20180133395A
(ko)
|
2016-02-25 |
2018-12-14 |
메모리얼 슬로안 케터링 캔서 센터 |
암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
WO2017205674A1
(en)
|
2016-05-25 |
2017-11-30 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic vaccinia virus mutants and using same for cancer treatment
|
|
WO2017209053A1
(ja)
|
2016-05-30 |
2017-12-07 |
アステラス製薬株式会社 |
新規な遺伝子組換えワクシニアウイルス
|
|
CA3070146A1
(en)
|
2016-07-19 |
2018-01-25 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic viruses targeting stat3
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
AU2017299983B2
(en)
|
2016-07-21 |
2021-01-07 |
Kolon Life Science, Inc. |
Recombinant vaccinia virus and use thereof
|
|
KR20230113832A
(ko)
|
2016-08-09 |
2023-08-01 |
시티 오브 호프 |
키메라 폭스바이러스 조성물 및 이의 용도
|
|
WO2018049248A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus equipped with bispecific engager molecules
|
|
AU2017332367B2
(en)
|
2016-09-21 |
2021-12-23 |
Stephen H. Thorne |
High mobility group box i mutant
|
|
WO2018058258A1
(en)
|
2016-09-30 |
2018-04-05 |
University Health Network |
Recombinant oncolytic viruses for cancer therapy
|
|
MX2021003013A
(es)
|
2018-09-15 |
2021-08-11 |
Memorial Sloan Kettering Cancer Center |
Poxvirus recombinantes para inmunoterapia contra cáncer.
|